Ten23 health® was founded in 2021 and acquired swissfillon in October 2021 and had rapid growth since then. The global contract development and manufacturing organization (CDMO) in Switzerland announced in September 2022 the completion of the superstructure of the new sterile manufacturing facility.
The existing FDA- and Swissmedic-inspected facility of ten23 health’s swissfillon in Visp already offers sterile manufacturing of pre-filled syringes, vials, and cartridges for clinical trial and commercial supplies, in close collaboration with ten23 health’s development center in Basel.
The new building, purpose-built for ten23 health, includes two further sterile manufacturing lines. Line 2 will produce large commercial quantities for market supply after regulatory approval of the drug. As a true scaled-up version of our existing filling line 1, the transfer between the lines will be associated with less risk for our biopharma customers. The fill line will be based on the latest Isolator technology to increase the safety of the drugs for patients. It will focus on complex products, filled into RTU containers including syringes, cartridges and special primary packaging such as used in specific administration devices for subcutaneous delivery. Fill line 3 will broaden ten23 health’s offering to also process bulk containers (vials), both in liquid and lyophilized form, with two large-scale freeze-driers, each at 12.5 square meters of shelf-space for clinical and commercial use.
ten23 health continues to hire additional colleagues to support the new production lines. A unique feature of the new facility is photovoltaic façade, covering the complete building exteriors, and being able to provide 45’000 kW per year. ten23 health facilities in Basel and Visp already operate with 100% renewable energy, consistent with our commitment to the planet.
Prof. Dr. Hanns-Christian Mahler, CEO of ten23 health, commented: “The completion of the initial phase of construction is a major milestone for ten23 health, our customers and their patients, and towards providing a significant amount of capacity for commercial and clinical sterile medicines for patients. In addition to securing renewable energy for the facility, we are investing in photovoltaics across the whole façade. We are excited to continue building ten23 health into a leading sustainable contract development and manufacturing worldwide.”
More about ten23 health
ten23 health®, located in Basel, Switzerland, is the human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups: we develop, manufacture, and test modern medicines. We support our clients in developing differentiated, stable, usable, and safe injectable treatment options for patients. Swissfillon, located in Visp, Switzerland, is a world leader in the sterile production of complex pharmaceutical dosage forms and a wholly-owned subsidiary of ten23 health.
ten23 health combines the latest scientific findings with proven and tested world-class industry and regulatory expertise to forge new paths for supporting clients. We provide our innovative services in a fair and sustainable manner, respecting people’s health and the future of our planet. ten23 health is solidly financed through the long-term commitment of 3i Group, an internationally reputable equity partner.
About the company’s name
The numeric value for the number of molecules in a sample of one mol is called the Avogadro constant and equals 6.022 * 10 23. The world is built from small units, and not a homogeneous mass.